

# Dinatale Rg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6160378/publications.pdf>

Version: 2024-02-01

30  
papers

854  
citations

840585

11  
h-index

552653

26  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1134  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
2	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
3	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	5.8	46
4	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
5	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, e200230.		37
6	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>European Urology</i> , 2021, 79, 468-477.	0.9	35
7	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. <i>Journal of Urology</i> , 2018, 200, 275-282.	0.2	31
8	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	3.2	30
9	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	1.6	29
10	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	1.6	28
11	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	1.6	21
12	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cyto-reductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	2.6	20
13	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. <i>British Journal of Anaesthesia</i> , 2020, 125, e402-e404.	1.5	15
14	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. <i>Modern Pathology</i> , 2022, 35, 825-835.	2.9	14
15	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	3.2	12
16	Evolving biological associations of upfront cyto-reductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	2.0	12
17	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.	1.6	11
18	Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and Survival. <i>Cancer Research</i> , 2021, 81, 1101-1110.	0.4	10

#	ARTICLE	IF	CITATIONS
19	Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 755-762.	0.8	9
20	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. <i>Urology</i> , 2020, 136, 169-175.	0.5	9
21	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 916-923.	0.8	8
22	Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum. <i>European Urology</i> , 2019, 76, 612-614.	0.9	7
23	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	7.7	7
24	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	0.8	6
25	Preoperative nomogram predicting 12-year probability of metastatic renal cancer " evaluation in a contemporary cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 853.e1-853.e7.	0.8	6
26	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365.	1.2	3
27	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma " An exploratory analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 791.e17-791.e24.	0.8	3
28	An evaluation of the role of tumor load in cytoreductive nephrectomy. <i>Canadian Urological Association Journal</i> , 2020, 14, E625-E630.	0.3	1
29	Urethral Melanoma " Clinical, Pathological and Molecular Characteristics. <i>Bladder Cancer</i> , 2022, 8, 291-301.	0.2	1
30	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 101-102.	0.2	0